Literature DB >> 29703790

Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.

Patrice Cacoub1,2,3,4, Anne Claire Desbois1,2,3,4, Cloe Comarmond1,2,3,4, David Saadoun1,2,3,4.   

Abstract

BACKGROUND AND AIMS: Extrahepatic manifestations of HCV are responsible for morbidity and mortality in many chronically infected patients. New, interferon-free antiviral treatment regimens, which present the opportunity to treat all HCV-infected patients, call for a better understanding of the benefits of treating non-cirrhotic chronically infected individuals.
METHODS: A systematic review was conducted. Identified studies from targeted database searches on Embase and Medline were screened. The methodological quality of the included publications was evaluated. Random-effect model meta-analyses were performed. Strength of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation system.
RESULTS: Data were extracted from a total of 48 identified studies. Achieving sustained virological response (SVR) was associated with reduced extrahepatic mortality (vs no SVR, OR 0.44 (95% CI 0.28 to 0.67)). SVR was associated with higher complete remissions in patients with cryoglobulinemia vasculitis (OR 20.76 (6.73 to 64.05)) and a higher objective response in those with malignant B-cell lymphoproliferative diseases (OR 6.49 (2.02 to 20.85)). Achieving SVR was also associated with reduced insulin resistance at follow-up (OR 0.42 (0.33 to 0.53)) and a significant protective effect on the incidence of diabetes (OR 0.34 (0.21 to 0.56)). Lack of randomised data comparing SVR versus non-SVR patients for the relevant extrahepatic indications attenuated these analyses.
CONCLUSION: Antiviral therapy can reduce extrahepatic manifestations related to HCV when SVR is achieved. Higher quality data, and reporting over longer follow-up periods, will be required to thoroughly explore comprehensive HCV treatment strategies. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  antiviral therapy; extrahepatic manifestations; hepatitis C; meta-analysis

Mesh:

Substances:

Year:  2018        PMID: 29703790     DOI: 10.1136/gutjnl-2018-316234

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection.

Authors:  Hashem B El-Serag; Israel C Christie; Amy Puenpatom; Diana Castillo; Fasiha Kanwal; Jennifer R Kramer
Journal:  Aliment Pharmacol Ther       Date:  2019-04-01       Impact factor: 8.171

2.  Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.

Authors:  Oluwaseun Falade-Nwulia; Mark S Sulkowski
Journal:  J Infect Dis       Date:  2020-11-27       Impact factor: 5.226

3.  Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals.

Authors:  Albert Do; Denise A Esserman; Supriya Krishnan; Joseph K Lim; Tamar H Taddei; Ronald G Hauser; Janet P Tate; Vincent Lo Re; Amy C Justice
Journal:  J Gen Intern Med       Date:  2020-04-27       Impact factor: 5.128

4.  Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Antonio Russo; Mariantonietta Pisaturo; Clarissa Camaioni; Roberta Astorri; Nicola Coppola
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Endocrine disorders associated with hepatitis C virus chronic infection.

Authors:  Michele Colaci; Lorenzo Malatino; Alessandro Antonelli; Poupak Fallahi; Dilia Giuggioli; Clodoveo Ferri
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

6.  Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes.

Authors:  Jia Li; Stuart C Gordon; Loralee B Rupp; Talan Zhang; Sheri Trudeau; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Mark A Schmidt; Yihe G Daida; Mei Lu
Journal:  Aliment Pharmacol Ther       Date:  2019-01-16       Impact factor: 8.171

7.  Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US.

Authors:  Wei Wang; Vincent Lo Re; Yi Guo; Hong Xiao; Joshua Brown; Haesuk Park
Journal:  Aliment Pharmacol Ther       Date:  2020-09-15       Impact factor: 8.171

8.  Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?

Authors:  Andre J Jeyarajan; Raymond T Chung
Journal:  J Infect Dis       Date:  2020-11-27       Impact factor: 5.226

Review 9.  Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population.

Authors:  Arun Rajasekaran; Ricardo A Franco; Edgar T Overton; Brendan M McGuire; Graham C Towns; Jayme E Locke; Deirdre L Sawinski; Emmy K Bell
Journal:  Kidney Int Rep       Date:  2021-04-25

Review 10.  Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy.

Authors:  Francesco Negro
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.